Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada – a time and motion study-Reference-Cited by-同舟云学术

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada – a time and motion study

Published:2012-10-29 Issue:1 Volume:12 Page:
ISSN:1472-6963
Container-title:BMC Health Services Research
language:en
Short-container-title:BMC Health Serv Res

Author:

Shinder Gayle A,Paradis Pierre Emmanuel,Posman Marianne,Mishagina Natalia,Guay Marie-Pascale,Linardos Dina,Batist Gerald

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Link

http://link.springer.com/article/10.1186/1472-6963-12-370/fulltext.html

Reference22 articles.

1. Canadian Partnership Against Cancer: The Future of Cancer Control in Canada. A discussion paper on pan-Canadian cancer control priorities for 2012–2017. 2011, Toronto, ON: CPAC

2. Bending MW, Trueman P, Lowson KV, Pilgrim H, Tappenden P, Chilcott J, Tappenden J: Estimating the direct costs of bowel cancer services provided by the National Health Service in England. Int J Technol Assess Health Care. 2010, 26 (4): 362-369. 10.1017/S0266462310001078.

3. Cromwell I, van der Hoek K, Melosky B, Peacock S: Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real world cost effectiveness analysis. J Thorac Oncol. 2011, 6 (12): 2097-2103. 10.1097/JTO.0b013e31822f657a.

4. Mittmann N, Au H-J, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group: Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaulation of national cancer institute of canada clinical trials group, CO.17 Trial. J Natl Cancer Inst. 2009, 101 (17): 1182-1192. 10.1093/jnci/djp232.

5. Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP: Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial. Br J Cancer. 2006, 94: 1122-1129. 10.1038/sj.bjc.6603059.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective;Future Oncology;2024-06-24

2. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma;PLOS ONE;2022-01-24

3. The burden of recording and reporting health data in primary health care facilities in five low- and lower-middle income countries;BMC Health Services Research;2021-09

4. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients;Expert Review of Pharmacoeconomics & Outcomes Research;2020-12-22

5. Oncology Information System: A Qualitative Study to Identify Cancer Patient Care Workflows;Journal of Medicine and Life;2020-10